Simpler Grants.gov #HT942526MSRPCTA

Multiple Sclerosis Clinical Trial Award Solicitation

This opportunity invites applications for clinical trials targeting multiple sclerosis, managed by the Defense Health Agency and the US Army Medical Research Acquisition Activity. - Government Buyer: - Defense Health Agency (DHA), Defense Health Agency Research and Development, Defense Health Agency Contracting Activity - US Army Medical Research Acquisition Activity (USAMRAA) - OEMs and Vendors: - No specific OEMs or vendors are named; the award is for clinical research, not product procurement - Products/Services Requested: - Clinical trial implementation for multiple sclerosis - Includes evaluation of new products, drugs, biologics, devices, clinical guidance, and emerging technologies - Two funding levels: - Level 1: Small-scale, proof-of-principle trials (up to $1M, 3 years) - Level 2: Larger phase 1 or 2 trials (up to $2M, 4 years) - Unique/Notable Requirements: - Applicants must address at least one MSRP Clinical Trial Award focus area (repair/neuroprotection/remyelination or treatment of MS symptoms) - Preliminary data relevant to the proposed clinical trial is required - Regulatory compliance is mandatory - Eligible applicants include U.S. Department of War organizations, as well as foreign and domestic, for-profit and nonprofit entities - No cost sharing required - Estimated Contract Value: - Total funding available: approximately $4,000,000 - About three awards expected - Place of Performance and Delivery: - Defense Health Agency Research and Development - Defense Health Agency Contracting Activity - US Army Medical Research Acquisition Activity

Description

The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials aimed at significantly impacting the treatment or management of multiple sclerosis. The award offers two funding levels: Level 1 supports small-scale, proof-of-principle clinical trials, while Level 2 supports larger-scale phase 1 or phase 2 clinical trials demonstrating preliminary safety or efficacy. Eligible applicants include extramural and intramural U.S. Department of War organizations, including foreign and domestic, for-profit and nonprofit entities. The total funding amount is approximately $4,000,000 to support about three awards, with no cost sharing required.

View original listing